Sanofi, Regeneron to refile Dupixent for skin condition after new study win
The FDA issued a rare rejection for Sanofi and Regeneron’s Dupixent about a year ago, asking for more efficacy data before it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
